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Abstract
OBJECTIVES: To describe the validation of a sensitive high performance liquid
chromatography tandem mass spectrometry (LC-MS/MS) method allowing the
simultaneous quantification of darunavir (DRV) and etravirine (ETR) in peripheral
blood mononuclear cells (PBMCs) and its application in a cohort of HIV-1
infected patients. METHODS: Blood samples were obtained from 110 patients.
PMBCs were isolated using density gradient centrifugation. Drug extraction
from PBMCs was performed with a 60:40 methanol-water (MeOH-H2O)
solution containing deuterated IS (DRV-d9 and ETR-d8). The chromatographic
separation was performed on a RP18 XBridge™ column. RESULTS: The
geometric mean (GM) of cell associated concentration ([DRV]CC) and
plasmatic concentration ([DRV]plasma) were 360.5ng/mL (CI95%:294.5-441.2)
and 1733ng/mL (CI95%:1486-2021), respectively. A geometric mean intracellular
(IC)/plasma ratio (GMR) of 0.21 (CI95%:0.18-0.24) was calculated. Adjusted for
dose/body surface area and post-intake t...
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Objectives: To describe the validation of a sensitive high performance liquid chromatography tandem mass
spectrometry (LC–MS/MS) method allowing the simultaneous quantiﬁcation of darunavir (DRV) and etravirine
(ETR) in peripheral blood mononuclear cells (PBMCs) and its application in a cohort of HIV-1 infected patients.
Methods: Blood samples were obtained from 110 patients. PMBCs were isolated using density gradient cen-
trifugation. Drug extraction from PBMCs was performed with a 60:40 methanol–water (MeOH–H2O) solution
containing deuterated IS (DRV-d9 and ETR-d8). The chromatographic separation was performed on a RP18
XBridge™ column.
Results: The geometric mean (GM) of cell associated concentration ([DRV]CC) and plasmatic concentration
([DRV]plasma) were 360.5 ng/mL (CI95%:294.5–441.2) and 1733 ng/mL (CI95%:1486–2021), respectively. A geo-
metric mean intracellular (IC)/plasma ratio (GMR) of 0.21 (CI95%:0.18–0.24) was calculated. Adjusted for dose/
body surface area and post-intake time, a statistically signiﬁcant correlation was observed between [DRV]Plasma
and the eGFR (p= 0.002) and between [DRV]Plasma and the concomitant use of ETR (p= 0.038). For the 10 pa-
tients receiving ETR in addition to DRV, the GMof [ETR]Plasma (available for 8 out of 10 patients) and [ETR]CCwere
492.3 ng/mL and 2951 ng/mL respectively. The GMR of ETR was 7.6 (CI95%: 3.61–13.83).
Conclusions: A handy and sensitive high performance LC–MS/MSmethod allowing the simultaneous quan-
tiﬁcation of DRV and ETR in PBMCs has been described and successfully applied in the largest cohort of DRV-
treated patients reported to date. ETR accumulates more efﬁciently in PBMCs compared to DRV. We have also
highlighted a possible impact of ETR on DRV plasma concentrations requiring further investigations.
© 2015 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
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1. Introduction
Darunavir (Prezista®DRV) is a potent protease inhibitor (PI) used as
a component of highly active antiretroviral therapy (HAART) in combi-
nation with the pharmacokinetic (PK) booster ritonavir for the treat-
ment of Human Immunodeﬁciency Virus-1 (HIV-1) infected patients
[1,2]. Etravirine (Intelence® ETR) is another anti-HIV-1 drug belonging
to the non-nucleoside reverse transcriptase inhibitor (NNRTI) class
employed for the management of HIV-1 infections in the presence of
viral mutations associated with NNRTI resistance [3].
Therapeutic drug monitoring (TDM) of antiretrovirals (ARV) based
on drug plasma concentrations is currently widely available to control
anti-HIV therapy [4–6]. This reactive strategy allows clinician to better
manage the risk of drug under- and over-exposure. Nevertheless,
while drug overshoot is thought to be directly linked to the occurrence
and the severity of adverse drug reactions (ADRs) [5], it is not clear
whether drug plasma level is an indicator of its effectiveness. Indeed,
the targets of PIs andNNRTIs are viral proteins locatedwithin the infect-
ed cells. Thus, at least intuitively, it appears that intracellular (IC) con-
centrations of ARV drugs should better correlate with their efﬁcacy
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than plasma concentrations. Therefore, quantitative determination of
DRV and ETR in human peripheral blood mononuclear cells (PBMCs)
may more adequately reﬂect treatment effectiveness than quantiﬁca-
tion of these drugs in plasma [7–12].
Previously, only fewmethods have been developed for the quantiﬁ-
cation of both antiretroviral drugs in PBMCs [13,14]. The present paper
describes the development and the full validation of a handy and sensi-
tive high performance liquid chromatography tandemmass spectrome-
try (LC–MS/MS) method allowing the simultaneous quantiﬁcation of
DRV and ETR in PBMCs and its clinical application in a cohort of 110
naïve and experienced HIV-1 infected patients.
2. Material and methods
2.1. Study design
HIV-1 infected patients were recruited from the AIDS Reference
Centre of the Cliniques Universitaires Saint-Luc (Brussels, Belgium)
between November 2012 and February 2014. Patients of 18 years
and older with conﬁrmed HIV-infection and treated by DRV with/
without ETR for at least one month prior to inclusion were eligible
for the study.
In addition to the samples routinely collected for the clinical follow-
up of the patient (viral load, CD4 cell count), two additional samples
used for determination of trough plasma and IC concentrations were
drawn immediately before next drug intake, with the highest timing
precision conceivable given the ambulatory context of the study recruit-
ment. In order to obtain a post-intake delay as close as possible to the
trough concentration sampling time, each patient was contacted by
phone a few days before the day of the visit for the study to be asked
not to take the medication prior to blood sampling.
The protocol (NCT02514369) was approved by the local ethical
committee (B403201214460) and a written informed consent was ob-
tained from each patient taking part to the study.
2.2. Chemicals and reagents
DRV, ETR, and their respective deuterated internal standards (IS)
DRV-d9 and ETR-d8 were purchased from Toronto Research Chemicals
(Ontario, Canada); methanol HPLC grade from Biosolve (Dieuze,
France); formic acid from Sigma-Aldrich (Seelze, Germany) and the
Dulbecco's phosphate buffered saline (DPBS) solution from Invitrogen
(Life Technologies, Gent, Belgium). HPLC grade water was produced
with Milli-Q water puriﬁcation system by Millipore (Darmstadt,
Germany). Blank PBMCs used for calibration curves and quality control
(QC) samples were isolated from the blood of healthy volunteers.
PBMCs count was performed on a Sysmex K-1000 haematology analyz-
er (Norderstedt, Germany).
2.3. LC–MS/MS system and chromatographic conditions
DRV and ETR measurements were performed by LC–MSMS, using a
Quattromicro tandem-mass spectrometer (Micromass UK, Manchester,
UK) ﬁtted with a Z-spray ion source. The instrument was directly
coupled to a Waters 2795 Alliance (high throughput) HT LC system,
with an integrated auto sampler thermostated at 10 °C (Waters,Milford,
USA). The chromatographic separation was performed on RP18 2.5 μm
column (2.1 × 75 mm) (Waters, Milford, MA, USA) maintained at
35 °C. The 20 μL injected aliquot was eluted at a mobile phase ﬂow
rate of 0.3 mL/min. The mobile phase consisted of water (eluent
A) and methanol (eluent B), both containing 10 mM formic acid. Initial
eluent composition was 90% A directly followed by a linear 1.0 min
ramp to 10% A, which was maintained for 4.49 min. The mobile phase
returned to 90% A at 5.5 min. Equilibration time was 1 min. Ionization
was in the positive ionmode using the following settings: capillary volt-
age 3.5 kV, cone voltage 22/22/54/54 V (DRV/DRV-d9/ETR/ETR-d8),
source temperature 125 °C, desolvation temperature 300 °C at a ni-
trogen ﬂow of approximately 650 L/h, and collision gas (high-purity
argon) pressure 3 · 10–3 bar. DRV, DRV-d9, ETR, and ETR-d8 were
monitored in multiple reaction monitoring mode (MRM) by detect-
ing speciﬁc product ions: DRV m/z 548.24 N 113.2, DRV-d9 m/z
557.36 N 401.26, ETR m/z 435.09 N 144.4, ETR-d8 m/z 443.18 N 304.33.
Collision energies were 21/15/49/45 for DRV/DRV-d9/ETR/ETR-d8
respectively.
2.4. Collection of PBMCs from patients
About 8 mL of blood was collected in cell preparation tube (CPT)
from Becton Dickinson Vacutainer® systems. Blood samples were ﬁrst
centrifuged at 1850 ×g for 15 min at room temperature (RT). The cell
layer was collected with a Pasteur pipette and transferred to a 15 mL
size conical centrifuge tube. The volume was completed to 15 mL with
cold DPBS to block enzymatic activity and to avoid active transport
out of the cells [15]. PBMCs were then washed 2 times according to
the manufacturer's instructions (at 650 ×g for 10 min at 4 °C). The cell
pellet was resuspended in 1 mL of DBPS. 20 μL aliquot was diluted in
180 μL of DBPS and directly used for cell counting using a Sysmex ana-
lyzer. After a ﬁnal centrifugation of the remaining 980 μL at 650 ×g
(10 min at 4 °C), the supernatant was aspirated and the cell pellet was
stored immediately at −80 °C until the day of drug extraction. This
method was adapted from Elens et al. [8].
2.5. Preparation of blank PBMCs
Approximately 8 mL of blood from healthy volunteers was collected
in heparin tubes (Sarstedt Monovette) and was transferred in
LeucoSepTM tubes (Greiner Bio-One, Kremsmünster, Austria). Blood
samples were centrifuged at 800 ×g for 20 min according to the
manufacturer's instructions. The thin mononuclear layer was collected
and successively washed twice with DPBS (at 250 ×g for 10 min). The
ﬁnal dry cell pellet was stored at−20 °C.
2.6. Stock solutions, calibrators and quality controls
DRV and DRV-d9 stock solutionswere obtained by diluting the com-
pounds in methanol to reach a ﬁnal concentration of 0.5 mg/ml and
1 mg/ml, respectively. ETR and ETR-d8 were diluted in chloroform to
obtain a concentration of 1 mg/ml. All stock solutions were then kept
at −20 °C. A working solution of DRV and ETR at a concentration of
1250 ng/ml was prepared in 60:40 MeOH:H2O. Similarly, a solution of
DRV-d9 andETR-d8 at a concentration of 4000ng/mlwas also prepared.
DRV and ETRworking solutionswere diluted in 60:40MeOH:H2O to
obtain 6 calibrators (1.25, 6.25, 12.5, 62.5, 93.75, 125 ng/ml) and 3 QC
solutions (2.5, 25, 75 ng/ml) containing all DRV-d9 and ETV-d8 at a
ﬁxed concentration of 20 ng/ml.
2.7. Sample processing
Blank PBMCs were thawed at RT and resuspended in 400 μL of the
calibrators or QC diluted in the extraction solution (60:40 MeOH:H2O
solution containing DRV-d9 and ETR-d8 at 20 ng/ml). PBMCs from
HIV-infected patients were resuspended with 400 μL of the cell ex-
traction solution. After vortex mixing (10 s), the resuspended pellets
were sonicated for 5 min and subsequently placed on a horizontal
shaker at 250 rpm for 6 h. The mixture was ﬁnally centrifuged
(10,500 ×g, 10 min) and the supernatant was transferred to an auto-
matic autosampler vial.
2.8. Analytical method validation
The assay was fully validated according to the U.S. Food and Drug
Administration (FDA) [16].
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2.8.1. Linearity
Five calibrations curves on three separate days were run during the
validation procedure. Each calibration curve was obtained using the six
calibrators and a blank control (1.25, 6.25, 12.5, 62.5, 93.75, 125 ng/ml).
2.8.2. Precision, accuracy, lower limit of quantiﬁcation and limit of
detection
Accuracy and precision of the method were determined through
the evaluation of ﬁve replicates at the three QC concentrations on
three consecutive validation days (n = 15). Accuracy was expressed
as the bias (% deviation) from nominal concentration while precision
was expressed as the coefﬁcient of variation in % (CV). Within and
between days precision (% CV) at each concentration level should not
be greater than 15%. Similarly, intra- and inter-day accuracy should be
within two standard deviations from the nominal concentration.
Lower limit of quantiﬁcation (LLOQ) was estimated by quantifying
blank PBMCs spiked with decreasing concentrations of DRV and ETV
and was deﬁned as the lowest concentration, of 10 replicates, with an
accuracy positioned between 80% and 120% of the nominal concentra-
tion with a CV lower than 15%. Limit of detection (LOD) was estimated
as the lowest concentration giving chromatographic peaks with a
signal-to-noise ratio N 3.
2.8.3. Extraction recovery
Extraction recovery was evaluated in ﬁve replicates at two concen-
trations by comparing the mean peak area responses of blank PBMCs
spiked at two concentrations (5 ng/ml, 100 ng/ml) to those of a pure
spiked solution (60:40 MeOH:H2O) representing 100% recovery. In
order to meet acceptance criteria, the extraction recovery should be be-
tween 80 and 120% and must be quite stable.
2.8.4. Speciﬁcity and selectivity
The selectivity was assessed by analysing a set of 15 different blank
PBMCs.
2.8.5. Matrix effect
The post-extraction addition technique has been used to estimate
matrix effect [17]. For both DRV and ETR, matrix effect was determined
at the three QC levels and LLOQ concentrations (2.5, 25, 75 and
1.25 ng/mL) in 6 replicates, using 6 different-drug-free PBMCs samples
(obtained from different healthy individuals) for each aliquot.
2.8.6. Determination of cell associated concentration: [DRV]CC and [ETR]CC
Based on the calibration curves, drug concentrations in the cell ex-
tracts were ﬁrst expressed in ng/ml. The absolute amount of DRV and
ETV (ng) in PBMCswas obtained bymultiplying the drug concentration
by 0.4 (400 μL of extraction solution). This amount was then divided by
the number of cells present in the cell extract (in millions) and the
PBMC concentration (also in ng/ml) was ﬁnally calculated assuming a
mean PBMC volume of 0.4 pL [8,11].
2.9. Determination of plasma drug concentration: [DRV]plasma and
[ETR]plasma
For eachpatient, blood samples dedicated to plasma drug quantiﬁca-
tion were obtained on heparinised tubes collected simultaneously
with the CPT Vacutainer® tubes. They were immediately centrifuged
at 1125 ×g for 10 min at RT. Plasma was then collected and stored at
−20 °C until the day of quantiﬁcation. Concentrations of DRV in
plasma ([DRV]plasma) and ETR in plasma ([ETR]plasma) were deter-
mined using a ultra high-pressure liquid chromatography (UPLC)
with diode array detection (DAD) [18] that is presently routinely
used in our laboratory. Using this validated method, the laboratory
has obtained successful results in the external quality assessment
scheme organized by SKML (The Netherlands) on antiretroviral drugs
including DRV and ETR.
2.10. Statistical analysis
Statistical analysis was performed using SPSS Software package
version 22 for Mac (SPSS Inc., Chicago, IL, USA). DRV and ETR plasma
and IC concentrations were log-transformed for normalisation of the
distribution. Descriptive statisticswere then calculated and are reported
as inverse log values. To assess the possible inﬂuence of categorical var-
iables such as ethnicity, gender, or concomitant use of other antiretrovi-
ral drugs on different PK parameters, Student t-test (2 groups) or one-
way ANOVA (N2 groups) were used.
Linear regressions were performed to assess the impact of each con-
tinuous variable such as age, post-intake delay, body mass index and
renal function (evaluated by estimated glomerular ﬁltration rate
(eGFR) assessed by the Modiﬁcation of Diet in Renal Disease (MDRD))
on PKparameters.Multivariate linear regressionswere performed to es-
timate the inﬂuence of these variables adjusted for individual doses of
the drugs reported on body surface area and for post-intake time.
Finally, [DRV]plasma and [DRV]cc were studied simultaneously in
generalized estimating equation (GEE). Regressions were computed
by quasi-least-squares, estimating the correlation between the two de-
pendent variables according to Chaganty and Shults [19]. Signiﬁcance
was estimated by chi-score on robust sandwich variance [20].
All tests were considered as statistically signiﬁcant for bilateral
p-values ≤ 0.05.
Based on the link between [DRV]plasma and different post-intake
times, an estimated half-life (T1/2) was calculated by linear regression
of the natural logarithm of the individual DRV concentrations against
the post-intake times. This estimation has the drawback of not having
successive points for the same patient.
3. Results
3.1. Validation results
Typical chromatograms of DRV and ETR samples at LLOQ are shown
in Fig. 1.
The assay was linear over the tested concentration range of
1.25–125 ng/ml for DRV and ETV. The equations of the lines for each
drug were y = 0.040x–0.007 and y = 0.070x–0.035 for DRV and ETR,
respectively with correlation coefﬁcients (r²) always greater than 0.99
(p b 0.0001).
The method was accurate and precise with respectively bias always
lower than two standard deviations from the nominal concentration
and CV ranging from 4.6 to 14.3% (Table 1). The LOD and LLOQ values
were 0.60 and 1.25 ng/ml for DRV and 0.62 and 1.25 ng/ml for ETR.
All recovered concentrations were within 80–120% of nominal con-
centrations (5 and 100 ng/ml) and showed a good reproducibility (CV
ranging from 2.5 to 10.7%).
Blank PBMCs did not show any interference for the speciﬁed ions
detected.
At the three QC, matrix effect was acceptable, with ion
suppression b 10% for DRV, ETR and internal standard (Table 1).
3.2. Clinical application of the method
In total, 110 HIV-positive patients participated to the study. All
quantiﬁcation analyses have been performed on the same day to mini-
mize the variability of the results.
4 patients were excluded because of a suspicion of a noncompliance
in the presence of an uncontrolled viral replication ([DRV]CC and
[DRV]Plasma were bLOD). Two other patients had a [DRV]CC b LOD solely
and were then excluded.
67.3 % of the patients were treatment-naïve receiving DRV boosted
by ritonavir (DRV/r) 800 mg/100 mg QD while 30.7% of the population
consists of treatment-experienced patients receiving DRV/r 600 mg/
100 mg BID. Two patients had unusual posology (DRV/r 600 mg/
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100 mg and 900 mg/100 mg, respectively). The general characteristics
of the patients are listed in Table 2.
The geometric mean of [DRV]CC and [DRV]plasma was 360.5 ng/ml
(CI95% 294.5–441.2 ng/ml) and 1733 ng/ml (CI95% 1486–2021 ng/ml),
respectively. The geometric mean of [DRV]CC was 342.5 ng/ml and
518.1 ng/ml for the patients receiving DRV/r QD versus BID respectively
(p = 0.083).
A good correlation between cell-associated and plasmatic concen-
trations was observed (r² = 0.501, b = 0.930 p-value b 0.0001,
Fig. 2A), i.e. about 50% of the variability of the DRV cell-associated
concentration could be explained by the plasma concentrations. A geo-
metric mean IC/plasma ratio (GMR) of 0.21 (CI95% 0.18–0.24) was
calculated.
In univariate analysis, there was no statistically signiﬁcant corre-
lation between age, gender, ethnicity, weight or concomitant use of
other antiretroviral drugs and [DRV]Plasma (Supplemental data Table 1).
A statistically signiﬁcant relationship between the eGFR and [DRV]Plasma
was observed (r2 = 0.058 p = 0.014, Supplemental data Table 1,
Fig. 3). In the model, it appeared that [DRV]Plasma increases by a factor
of 1666 when GFR decreases by 50%.
Adjusted for dose/body surface area and post-intake time by multi-
variate regression, a statistically signiﬁcant correlation was observed
between [DRV]Plasma and the eGFR (r²=0.329 p=0.002, Supplemental
data Table 1) and between [DRV]Plasma and the concomitant use of ETR.
ETR co-administration multiplies the [DRV]Plasma by a factor of 0.51
(r² = 0.321 p = 0.038, Supplemental data Table 1).
The T1/2 was calculated as 10.75 h (CI95% 8.01–16.33) for the
[DRV]Plasma and 12.91 h (CI95% 8.12–31.59) for the [DRV]cc. After exclu-
sion of the 10 patients with ETR, the T1/2 became 10.92 (CI95%
8.14–16.56) and 13.25 (CI95% 8.31–32.77) h for [DRV]Plasma and
[DRV]cc, respectively. Correlation between post-intake time and
[DRV]plasma for patients with or without ETR is shown in Fig. 4. The
T1/2 for the 10 patients with ETR was calculated as 3.33 h (CI95%
2.31–5.99) and 2.03 h (CI95% 1.52–3.09) for [DRV]Plasma and [DRV]cc,
respectively. These differences in the plasma and IC T1/2 with orwithout
concomitant use of ETR are statistically signiﬁcant (p=0.006 and 0.002
for [DRV]Plasma and [DRV]cc, respectively).
Consistently, GEE for simultaneous analysis of [DRV]Plasma and
[DRV]cc adjusted for dose/body surface area and post-intake time con-
ﬁrms they are signiﬁcantly correlated with the following factors:
• concomitant use of ETR (p = 0.038)
• eGFR (p = 0.005).
The ratio IC/plasma of DRV shows no signiﬁcant interactionwith the
factors studied.
For the 10 patients receiving concomitant ETR, the geometric mean
of [ETR]Plasma (available for 8 out of 10 patients) was 542.6 ng/ml
Fig. 1.DRV and ETR typical chromatograms of PBMC extract obtained either with a blank sample (A, E) and internal standard (D, H) or with a LLOQ sample (B, F). In addition, two patient
ion chromatograms of PBMC extract (C–G) are reported. In these examples, DRV and ETR concentration was 10.4 ng/mL and 34.2 ng/mL (before transformation to obtain IC
concentrations), respectively. RT: retention time; ES+: electrospray positive mode; MRM of 4 channels: multiple reaction monitoring of 4 different ion transitions, Y axis express as
relative intensity (%).
Table 1
Accuracy (% deviation from nominal concentration), intra- and interassay precision (CV in
%) and matrix effect. (n = 5 in three separate runs).
Anti-HIV
drug
Nominal
Concentration
(ng/ml)
Accuracy
(%)
Intra-assay
precision (%)
Inter-assay
precision (%)
Matrix
effect
(%)
DRV 2.5 6.1 9.8 11.5 -8.1
25 3.6 4.7 5.8 -5.3
75 3.1 3.5 4.9 -7.8
ETV 2.5 3.2 12.1 14.4 -9.1
25 5.6 6 6 -8.3
75 6.2 4.6 4.6 -9.6
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(CI95% 326.9–900.7 ng/ml). The geometric mean of [ETR]CC was
3018 ng/ml (CI95% 1339–6800 ng/ml) but extremely variable
compared to plasma levels (CV = 124.2 versus 42.3%, respective-
ly). The GMR was 7.06 (CI95% 3.61–13.83). There was a borderline
signiﬁcant correlation between log[ETR]cc and log[ETR]plasma (r² =
0.566, b=1.43, p=0.031) but this relatively high p-valuemight be the
consequence of the low number of data for ETR (Fig. 2B). The slope
value was N1, probably reﬂecting that ETR accumulates more in the
cells than DRV. Given the low number of patients receiving ETR, it
was not possible to analyse the factors inﬂuencing its PK.
4. Discussion
The ﬁrst aim of our studywas to develop and validate a sensitive, ac-
curate and precise LC–MS/MS method for the simultaneous quantiﬁca-
tion of DRV and ETV in PBMCs. The use of deuterated IS allowed us to
validate our method over a range of 1.25–125 ng/ml in PBMCs matrix
(drug concentrations in the cell extracts before transformation in IC
concentration) for DRV and ETR with excellent correlation coefﬁcients
(r² N 0.99). Our method was proven to be accurate, precise and speciﬁc
at three different concentrations (low, medium and high) reﬂecting al-
most all scenarios in the clinical setting. The previous reportedmethods
used for DRV [11,21,22] or both DRV/ETR IC quantiﬁcation [13,14] did
not used deuterated drugs as IS. D'Avolio et al. were able to quantify
14 ARV in a unique chromatographic run [13]. However, their method
was based on a simple LC–MS detector which reduces the speciﬁcity
of the quantiﬁcationmethod compared to a tandemmass spectrometry
detector [13]. Moreover, they used Quinoxaline as unique IS for the 14
drugs which had not the same retention time than either DRV or ETR
(8.6 min for Quinoxaline versus 10.2 and 15.2 min for DRV and ETR, re-
spectively) and can thus not correct the signal for detection variability.
Additionally, the running time was reduced to 6.5 min versus 25 min
in their method. This is a considerable gain of time when analysis of
large batches of samples is performed, which situation is very frequent
in clinical and research studies. Both methods are quite similar in terms
of precision and accuracy. However, the sensitivity of their technique
Table 2
Patient characteristics at day of sampling.
Darunavir Prezista®
Number of patients in total 104
Number of patients according posology per day 600 mg (n = 1)
800 mg (n = 70)
900 mg (=1)
1200 mg (=32)
NNRTI ETR (n = 10) NVP (n = 2)
NNRTI-free (n = 92)
NRTI ABC/3TC (n = 15), FTC/TDF
(=56), 3TC (n = 13), TDF
245 mg (n = 3), NRTI-free
(n = 17)
RAL n = 29
MVC n = 10
Age (mean ± SD) 47.9 ± 12.1 years
Body Mass Index (mean ± SD) 25.45 ± 4.89
Gender Male = 68 (65.4%)
Female = 36(34.6%)
Ethnic origin Caucasian: 62 (59.6%)
African: 39 (37.5%)
Asian: 2 (1.9%)
South American: 1 (1%)
CD4 cell count (cells/mm3) median [min–max-IQR] 532 [33–1641–407]
Nadir (cells/mm3)
median [min–max-IQR]
144 [2–671–146]
HIV-1 RNA b 37 cps/ml: number of patients (%) 78 (75%)
HIV-1 RNA N 37 cps/ml: number of patients (%)
Median [min–max-IQR] cps/ml
26 (25%)
104 [41–64460–168]
Duration of treatment (mean ± SD) 21.8 ± 15, 2 months
GFR mean ± SD (MDRD) 86.97 ± 23.35
mL/min/1.73 m2
NNRTI: non-nucleoside reverse transcriptase inhibitors, NRTI: nucleoside reverse tran-
scriptase inhibitors, RAL: raltegravir, MVC: maraviroc ETR: etravirine, NVP: nevirapine,
ABC: abacavir, 3TC: lamivudine, FTC: emtricitabine, TDF: tenofovir disoproxil fumarate.
NNRTI-free: without any NNRTI.
NRTI-free: without any NRTI.
Fig. 2. Relationship between the IC and the plasma concentrations for DRV (A) and ETR (B), respectively, expressed in ng/ml.
Fig. 3. Effect of the eGFR on the [DRV]plasma. Lines represent the average trend ± SD.
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seems to be 10-fold better than ours. However, the sensitivity of our
method seems sufﬁcient to be applied in clinical setting (see clinical ap-
plication) and the loss of sensitivity is counterbalanced by a higher spec-
iﬁcity of LC–MS/MS compared to LC–MS. Recently, another method
using a ﬂuorescence detector has been reported but only for DRV IC
quantiﬁcation [21]. Even if probably more available in routine labs,
this detection system is less speciﬁc than tandem mass spectrometry.
Moreover, its sensitivity appeared substantially lower than the present
method with a linearity range of 5–100 ng/106 cells. Finally, their tech-
nique only allows DRV quantiﬁcation and not ETR while both drugs are
frequently co-administrated in HIV-1 experienced patients. Further-
more, this drug combination is characterized by huge PK variations
and both drugs can be victim and/or perpetrate PK interactions (see
below).
In a second step, the objective was to demonstrate that the method
could be easily applied to clinical situations by quantifying DRV and ETR
in a large cohort of 110 patients with 10 patients receiving both drugs in
combination. As expected and consistent with previous studies [23]
DRV concentrations in PBMCs and in plasma were extremely variable
with CV of 99.4 and 66.0 % respectively but noticeably higher than
the LLOQ, conﬁrming that the sensitivity of our technique was good
enough for its use in practice. Interestingly, a consistent correlation be-
tween log[DRV]Plasma and log[DRV]cc was observed with a slope of 0.93
(Fig. 2A).This probably indicates that DRV does not accumulate within
the cell as, for a large increase in plasma concentration, only a moder-
ately higher IC concentration is observed. Drug accumulation in cell is
not only a passive process but also includes dynamic transport. The
magnitude of cell accumulation clearly depends on multiple concomi-
tant mechanisms chieﬂy plasma protein binding, drug lipophilicity or
ionization and inﬂux/efﬂux transmembrane transport activity. DRV
has been identiﬁed as an ABCB1, OATP1A2 and ABCC2 substrate and
their activity could potentially modulate DRV passage into the cells
expressing those proteins and thus the relationship between plasma
and IC concentrations.
Despite similar [DRV]Plasma, the [DRV]cc reported here are lower than
those described in other studies [13,14]. In their study, Ter Heine et al.
found in cells Ctrough of 1450 ± 1110 ng/ml (mean ± SD, n = 10)
[14]. Consequently, the accumulation ratio observed was higher in
their cohort than in the present study, with values of 1.32 versus 0.21.
However, that study involved only 10 experienced patients receiving
600 mg/100 mg DRV/r BID while in our study, about 70% of patients
were naïve-treatment patients receiving 800mg/100mg DRV/r QD. In-
terestingly, it has been recently shown that RTV dosing signiﬁcantly af-
fects the extent of DRV penetration into the cerebrospinal ﬂuid [24].
Indeed patients receiving DRV/r QD showed not only lower CSF DRV
Ctrough but also lower CSF-to-plasma ratios (0.32% versus 0.90%),
suggesting that the penetration of the drug across the blood-brain-
barrier (BBB) (where ABCB1 is expressed) is lower in the once-daily
regimen than in the twice-daily regimen. This could be the consequence
of a dose-dependent RTV inhibition of transporters, suggesting possibly
that ABCB1 (also expressed in PBMCs [24,25]) is less inhibited with
lower doses of RTV and thus allows lower cell accumulation in the
case of a once-daily administration. This is in accordance with the fact
that the majority of our patients were naïve and thus treated with
lower doses of RTV. The second study that investigated the DRV IC PK
was reported by Jackson et al. [11]. In this study, the DRV IC AUC-to-
plasma ratio ranged between 4.9 and 5.6. In their cohort, all patients re-
ceived 800 mg/100 mg DRV/r QD in association with raltegravir (RAL)
800 mg in once or twice daily. In our cohort, only approximately 30%
of our patients were given RAL on a BID basis. Even if it is difﬁcult to de-
cipher the neat impact of these study design differences, we cannot ex-
clude that part of the discrepancies observed are due to differences in
treatment regimens. Another very conceivable explanation is certainly
methodological. Indeed, in their review, Bazzoli et al. summarized ﬁnd-
ings from studies on IC concentrations of antiretrovirals and highlighted
clear limitations, e.g. small patient numbers, poor study design and
methodological differences [7]. The differences between our IC concen-
tration values and those reported by Jackson [11] probably also come
from their analytical procedure and more precisely from the cell isola-
tion step using a single cycle of cell washing to remove drug contamina-
tion from plasma. In our method, 3 ice-cold washing steps of the cell
pellets are included as described in Elens et al. [8]. In this last study,
accumulation ratios were in the same range as in our study with 0.42
for Lopinavir (LPV/r) and 0.18 for Tipranavir (TPV/r). Jones et al. have
demonstrated a hierarchy in the in vitro IC accumulation of PIs with:
nelﬁnavir (NFV) N saquinavir (SQV) N ritonavir (RTV) N indinavir
(IDV) [26]. Later, Khoo et al. have conﬁrmed this tendency with accu-
mulation ratios of 4.01 for SQV/r and 0.29 for IDV/r, using a three-step
washing methodology [27]. In a recent conference report, D. Back
et al. (Liverpool) highlighted that the unique washing step methodolo-
gy potentially over-estimates IC concentration by inclusion of residual
plasma drug contamination and drug bound to cell membrane. Further-
more, it has been shown in a previous report that, following 60 min of
incubation of EFV-loaded PBMCs in a drug-freemedium at 4 °C, approx-
imately 97% EFV remained cell-associated compared to about 70% at
37 °C, reﬂecting that working at 4 °C limits analyte-loss during these
additional washing steps [15]. In conclusion, using quite similar meth-
odologies, we can place DRV/r in the same range of LPV/r, TPV/r and
IDV/r in the hierarchy of IC accumulation much lower than ETR.
Drug–drug interactions between antiretroviral drugs are complex
and remain a challenge when starting a treatment. It has been reported
that ETR is an inducer of CYP3A and a weak inhibitor of CYP2C9,
CYP2C19 and ABCB1Scholler-Gyure, Kakuda [28]. As DRV is primarily
metabolized by CYP3A and is a substrate of multiple ABC, including
ABCB1, ETR has the potential to modulate the DRV PK pathway by in-
ducing CYP3A and/or inhibiting ABCB1.
This kind of interaction was demonstrated for other PIs such as
atazanavir (ATV) and fosamprenavir (FPV) which are also metabolized
by CYP3A. In an open-label crossover study in 32 healthy volunteers, it
was shown that ETR co-administrated with unboosted ATV (400 mg
QD) or boosted ATV/r (300/100 mg) reduced ATV AUC24h by 17% and
14% respectively possibly because of induction of CYP3A by ETR [29].
In the same study, co-administration of ETR with ATV or ATV/r de-
creased ATV Ctrough by 47% and 38% respectively. FPV is the phosphate
ester prodrug of the PI amprenavir (APV). APV is the PI with the closest
structural resemblance to DRV [30] and is also a CYP3A/ABCB1 substrate
[31]. In a small cohort of 8 HIV-1 positive patients receiving boosted
FPV/r 700/100 mg BID, [APV]plasma and AUC12h-Cmin were signiﬁ-
cantly increased by 69% and 77% respectively in case of ETR co-
administration [32] potentially because of ABCB1 inhibition by ETR.
This latter observation raises the question about the relative importance
of CYP3A induction over ABCB1 inhibition with ETR co-administration.
Fig. 4. Correlation between post intake time and [DRV]plasma for patients with ETR (in red)
or without (in black). Lines represent the average trend ± SD. (For interpretation of the
references to colour in this ﬁgure legend, the reader is referred to the web version of
this article.)
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The opposite effect of ETR onATV on the one hand and onAPV PK on the
othermight be the consequence of a greater impact of CYP3A activity on
ATV PK while, considering APV, ABCB1 activity seems the most
inﬂuencing factor. In our cohort, we observed that ETR decreased
[DRV]plasma by approximately 50% by promoting a signiﬁcant decrease
in the T1/2 of DRV. This PK effect is potentially further due to the ETR-
mediated CYP3A-induction than the inhibition of ABCB1 activity that
would theoretically have led to an increased DRV exposure. Our obser-
vation probably reﬂects that CYP3A activity is more importantly impli-
cated in the PK pathway of DRV than ABCB1 and inﬂuences its T1/2.
Therefore, it appears clear that the clinical impact of this probably im-
portant drug interaction between ETR and DRV needs to be further
clariﬁed.
5. Conclusion
We have described a handy and sensitive high performance liquid
chromatography tandem mass spectrometry (LC–MS/MS) method
allowing the simultaneous quantiﬁcation of DRV and ETR in PBMCs.
This method was then applied in the largest cohort of DRV treated HIV
infected patients reported to date. Our intracellular plasma ratio of
DRV is lower than previously reported with the discrepancies probably
due to alternative treatment regimens and/or to methodological/
technical differences. ETR accumulates more efﬁciently in PBMCs
compared to DRV.
Interestingly, we have highlighted a possible impact of ETR on
DRV plasma concentrations but further investigations are needed
to clarify this interaction that might incriminate the CYP3A-
mediated metabolization pathway of DRV and its induction by ETR
co-administration.
Supplementary data to this article can be found online at http://dx.
doi.org/10.1016/j.clinbiochem.2015.12.011.
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